Related Experiment Video
Updated: May 29, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Screening for lung cancer: it works, but does it really work?
1Medical University of South Carolina, Charleston, 29425, USA. silvestr@musc.edu
Annals of Internal Medicine
|September 7, 2011
Summary
Physicians should cautiously consider low-dose computed tomography (LDCT) for lung cancer screening. While LDCT shows promise, widespread adoption requires more evidence to ensure benefits outweigh potential harms.
Area of Science:
- Oncology
- Radiology
- Public Health
Background:
- The National Lung Screening Trial (NLST) demonstrated a reduction in lung cancer deaths using low-dose computed tomography (LDCT).
- Physicians now face decisions regarding the widespread adoption of LDCT screening for high-risk populations.
- Lessons from other cancer screenings highlight potential overdiagnosis and overtreatment concerns.
Observation:
- LDCT screening in the NLST showed encouraging mortality reduction in a specific study population.
- Potential harms include false-positive findings leading to invasive diagnostic procedures.
- Risks may be amplified in general practice and among patients with smoking-related comorbidities.
Findings:
- Widespread implementation of LDCT screening is considered premature despite NLST results.
- The balance of benefit versus harm requires further evaluation, especially in diverse clinical settings.
- Morbidity and mortality associated with follow-up procedures are significant concerns.
Implications:
- Caution is advised before general adoption of LDCT for lung cancer screening.
- Further research is needed to optimize screening protocols and patient selection.
- Ensuring that screening benefits outweigh harms is crucial for responsible implementation.